Patient Baseline Demographics and Disease Characteristics
| . | Filgrastim . | SCF + Filgrastim . | Total . | P Value . |
|---|---|---|---|---|
| Sex (n) | ||||
| Female | 103 | 100 | 203 | — |
| Age (yr) | ||||
| Median (min, max) | 45.5 (27.1, 62.6) | 46.4 (26.7, 63.1) | 46.1 (26.7, 63.1) | .492 |
| Weight (kg) | ||||
| Median (min, max) | 65.5 (42.0, 114.0) | 70.1 (37.0, 123.2) | 66.8 (37.0, 123.2) | .096 |
| Baseline hematology | ||||
| ANC (×109/L) | ||||
| Mean (SD) | 3.80 (1.60) | 3.52 (1.69) | 3.67 (1.65) | .052 |
| Median (min, max) | 3.73 (0.82, 11.75) | 3.11 (0.78, 11.47) | 3.38 (0.78, 11.75) | |
| PLT (×109/L) | ||||
| Mean (SD) | 252 (84) | 245 (96) | 249 (90) | .295 |
| Median (min, max) | 247 (98, 591) | 224 (128, 935) | 238 (98, 935) | |
| Bone marrow involvement (all <10% involvement) | ||||
| n (%) | ||||
| No | 92 (89.3) | 97 (97.0) | 189 (94.5) | .121 |
| Yes | 8 (7.8) | 3 (3.0) | 11 (5.5) | |
| Unknown | 3 (2.9) | 0 (0) | 3 (1.5) | |
| Prior cycles of chemotherapy | ||||
| Median (min, max) | 5 (2, 22) | 5 (2, 17) | 5.0 (2, 22) | .946 |
| Prior cycles of cyclophosphamide | ||||
| Median (min, max) | 4 (0, 19) | 4 (0, 13) | 4 (0, 19) | .658 |
| Prior radiotherapy | ||||
| n (%) | ||||
| Yes | 29 (28.2) | 27 (27.0) | 56 (27.6) | .855 |
| No | 73 (70.9) | 72 (72.0) | 145 (71.4) | |
| Unknown | 1 (1.0) | 1 (1.0) | 2 (1.0) | |
| Disease stage | ||||
| n (%) | ||||
| II | 10 (9.7) | 13 (13.0) | 23 (11.2) | .810 |
| IIIA | 24 (23.3) | 19 (19.0) | 43 (21.2) | |
| IIIB | 15 (14.6) | 14 (14.0) | 29 (14.3) | |
| IV | 54 (52.4) | 54 (54.0) | 108 (53.2) |
| . | Filgrastim . | SCF + Filgrastim . | Total . | P Value . |
|---|---|---|---|---|
| Sex (n) | ||||
| Female | 103 | 100 | 203 | — |
| Age (yr) | ||||
| Median (min, max) | 45.5 (27.1, 62.6) | 46.4 (26.7, 63.1) | 46.1 (26.7, 63.1) | .492 |
| Weight (kg) | ||||
| Median (min, max) | 65.5 (42.0, 114.0) | 70.1 (37.0, 123.2) | 66.8 (37.0, 123.2) | .096 |
| Baseline hematology | ||||
| ANC (×109/L) | ||||
| Mean (SD) | 3.80 (1.60) | 3.52 (1.69) | 3.67 (1.65) | .052 |
| Median (min, max) | 3.73 (0.82, 11.75) | 3.11 (0.78, 11.47) | 3.38 (0.78, 11.75) | |
| PLT (×109/L) | ||||
| Mean (SD) | 252 (84) | 245 (96) | 249 (90) | .295 |
| Median (min, max) | 247 (98, 591) | 224 (128, 935) | 238 (98, 935) | |
| Bone marrow involvement (all <10% involvement) | ||||
| n (%) | ||||
| No | 92 (89.3) | 97 (97.0) | 189 (94.5) | .121 |
| Yes | 8 (7.8) | 3 (3.0) | 11 (5.5) | |
| Unknown | 3 (2.9) | 0 (0) | 3 (1.5) | |
| Prior cycles of chemotherapy | ||||
| Median (min, max) | 5 (2, 22) | 5 (2, 17) | 5.0 (2, 22) | .946 |
| Prior cycles of cyclophosphamide | ||||
| Median (min, max) | 4 (0, 19) | 4 (0, 13) | 4 (0, 19) | .658 |
| Prior radiotherapy | ||||
| n (%) | ||||
| Yes | 29 (28.2) | 27 (27.0) | 56 (27.6) | .855 |
| No | 73 (70.9) | 72 (72.0) | 145 (71.4) | |
| Unknown | 1 (1.0) | 1 (1.0) | 2 (1.0) | |
| Disease stage | ||||
| n (%) | ||||
| II | 10 (9.7) | 13 (13.0) | 23 (11.2) | .810 |
| IIIA | 24 (23.3) | 19 (19.0) | 43 (21.2) | |
| IIIB | 15 (14.6) | 14 (14.0) | 29 (14.3) | |
| IV | 54 (52.4) | 54 (54.0) | 108 (53.2) |